[ad_1]
WHO approved more direct-acting hepatitis antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection by 2020, helping income countries low and intermediate to increase the number of registered treatments and reduce the prices of a complete treatment in the United States. $ 100 – the update is as low as US $ 60 for three months and works to eliminate hepatitis C.
For the first time, this year’s report includes information on hepatitis C diagnoses. Focusing on selected countries with various HCV epidemics, the report provides updates on different dimensions of access. HCV diagnostics and pharmaceuticals, including product price, regulatory environment, and patent status, which together shape the national response to hepatitis in different contexts. It highlights the main areas of action of ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
Globally, as of the end of 2017, only 5 million – or 7% – of the 71 (62–79) million chronically infected people with HCV had cumulative treatment with DAAs. As countries continue to grapple with the disease burden and service disruption caused by the COVID-19 pandemic, it is critical to ensure that the momentum and recent gains in the hepatitis response C are not lost. Against this background, this report strongly reminds us to continue investing in building resilient and sustainable health systems focused on universal health coverage.
Source link
